https://amp.cnn.com/cnn/2024/06/17/asia/japan-record-spike-stss-bacterial-infection-intl-hnk

https://www.mdpi.com/2079-6412/14/9/1105

• to counter SRB-induced corrosion, recent research has explored using nanotechnology-based solutions.

•silver nanoparticles (AgNPs) and zinc oxide nanoparticles (ZnONPs) have shown efficacy in reducing SRB biofilm formation and protecting metals by creating anti-corrosive coatings.

•prevents SRB from accessing and adhering to metal surfaces in seawater, AgNPs reduced the corrosion rate by actively hindering SRB growth and disrupting their metabolic functions.

https://www.frontiersin.org/articles/10.3389/fmats.2023.1021335/full

•other approaches, like using high-entropy alloy nanoparticles (HEA-NPs), offer promising results in minimizing biofilm formation and corrosion rates, especially in environments with fluctuating temperatures and salinity.

https://www.frontiersin.org/articles/10.3389/fmats.2023.012345/full

• B. burgdorferi manipulates the mammalian host cells after its entry by modifying its glycoproteins, which help it to invade and propagate in different body tissues.

• B. burgdorferi can invade the triple-negative MDA-MB-231 breast cancer cells at a significantly higher rate in comparison to normal mammary epithelial cells.

1. Uropathogenic Escherichia coli (UPEC): The leading cause, responsible for most community and hospital-acquired UTIs.

2. Klebsiella pneumoniae: Another major cause, especially in healthcare settings.

3. Proteus mirabilis: Common in complicated UTIs, especially in catheterized patients.

4. Enterococcus faecalis and Staphylococcus saprophyticus: Often linked to hospital-acquired and community UTIs, respectively.

To manage and control excessive bacterial growth, treatment strategies include:

1. Antibiotics: Appropriate antibiotic therapy is essential, with drugs selected based on susceptibility testing to avoid resistance.

2. Non-Antibiotic Approaches: This includes cranberry extract, probiotics, and other supportive supplements, especially for recurrent infections.

3. Phage Therapy and Vaccines: Emerging therapies such as bacteriophage treatments and potential vaccines may offer future alternatives to combat resistant infections .

https://www.mdpi.com/2076-0817/12/4/623

Situation at a glance

Psittacosis is a respiratory infection caused by Chlamydophila psittaci (C. psittaci), a bacteria that often infects birds. Human infections occur mainly through contact with secretions from infected birds and are mostly associated with those who work with pet birds, poultry workers, veterinarians, pet bird owners, and gardeners in areas where C. psittaci is epizootic in the native bird population. The concerned countries have implemented epidemiological investigations to identify potential exposures and clusters of cases.

Symptoms

Fever, chills, and respiratory issues, treatable with antibiotics.

WHO Recommendation and Initiatives

Testing and Awareness: Clinicians should test suspected cases of C. psittaci using RT-PCR, and bird owners should be aware that pet birds, especially psittacines, may carry the pathogen without showing symptoms.

Quarantine and Veterinary Care: Newly acquired birds should be quarantined, and sick birds should be examined by veterinarians.

Surveillance: Monitoring C. psittaci in wild birds and testing samples from other avian disease investigations can help track the pathogen’s prevalence.

Hygiene: Bird owners should clean cages regularly, prevent droppings from spreading, avoid overcrowding, and maintains good hygiene, including frequent handwashing when handling birds and their environments.

Hospital Precautions: For hospitalized cases, standard infection control and droplet transmission precautions are recommended.

COMPLICATIONS

In short, complications of infection with C. psittaci include acute respiratory distress syndrome, respiratory failure, as well as endocarditis, myocarditis, sepsis, DIC, meningoencephalitis, hepatitis, and pancreatitis; rarely, the patient may present with a fulminant disease course characterized by multi-organ failure

TREATMENT

Treatment for this bacterial infection is based on intracellular activity, pharmacokinetics, and evidence from clinical trials that recommend tetracycline antibiotics, particularly doxycycline, as the preferred treatment.

Introduction to SIBO and EED

• Small Intestine Bacterial Overgrowth (SIBO) affects gut health.

• Environmental Enteric Dysfunction (EED) impacts childhood growth, particularly in low-income areas.

• EED causes small bowel dysfunction, leading to poor nutrient absorption and stunted growth.

• SIBO often worsens EED, complicating children’s health outcomes.

Impact of SIBO on Growth

• SIBO interferes with nutrient absorption, leading to growth issues.

• Studies show early SIBO can predict future stunting and developmental delays.

• Bacterial overgrowth in the gut affects physical and cognitive development.

Examples of Bacteria and Mechanism of Overgrowth

• Common SIBO bacteria: E. coli, Klebsiella, Enterobacter.

• Bacterial overgrowth happens due to factors like poor gut motility and contaminated food/water.

• In low-sanitation areas, bacterial imbalance grows, causing inflammation and poor nutrient uptake.

Impact on Gut Integrity

• SIBO damages gut structure:

• Causes villous atrophy and crypt elongation.

• Weakens gut lining, increasing infection risk and reducing nutrient absorption.

Link to Poor Sanitation

• SIBO and EED are common in areas with poor water and sanitation (WASH).

• Lack of hygiene leads to repeated exposure to pathogens and bacterial overgrowth

1. Dysbiosis and Ocular Diseases: Alterations in gut microbiota, referred to as dysbiosis, have been implicated in various ocular conditions, including uveitis, dry eye disease, age-related macular degeneration (AMD), and glaucoma. Dysbiosis can disrupt immune regulation and promote inflammation, leading to ocular tissue damage and disease progression.

2. Immune Modulation: The gut microbiota plays a crucial role in modulating the immune system. Changes in gut microbial composition can influence the activity of immune cells in the lacrimal gland and ocular surface, which are critical for maintaining eye health and preventing inflammatory diseases.

3. Metabolite Production: Gut bacteria produce metabolites that can have either anti-inflammatory or pro-inflammatory effects. For instance, short-chain fatty acids produced by certain gut bacteria are beneficial for immune health, while other by-products may exacerbate inflammation associated with ocular diseases.

4. Connection to Specific Eye Conditions:

- Uveitis: Gut dysbiosis may increase intestinal permeability, allowing microbial products to trigger ocular inflammation through direct effects or immune sensitization mechanisms.

- Dry Eye Disease: Changes in osmolarity linked to dysbiosis have been observed in dry eye conditions, suggesting a relationship between gut health and tear film stability.

- AMD: Specific bacterial strains associated with dysbiosis have been found more frequently in individuals with advanced AMD, indicating a potential role of gut health in retinal diseases.

- Glaucoma: Research indicates that gut microbiota may influence neurodegeneration in glaucoma through inflammatory pathways activated by bacterial components like lipopolysaccharides (LPS).

5. Therapeutic Approaches: Strategies aimed at restoring gut microbiota balance, such as probiotics, prebiotics, synbiotics, and fecal microbiota transplantation, show promise for preventing and managing ocular diseases. These interventions may help improve immune function and reduce inflammation associated with various eye disorders.

In summary, the interplay between gut microbiota and ocular health is complex but crucial for maintaining homeostasis on the ocular surface. Understanding this relationship opens new avenues for therapeutic interventions targeting gut health to improve eye conditions.

https://www.sciencedirect.com/science/article/pii/S1350946224000156#sec5

•Common symptoms include bloating, gas, abdominal pain, and diarrhea.

•SIBO can be associated with conditions like irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).

•Diagnosis often includes breath tests to measure gas levels.

•Treatment usually involves antibiotics, dietary changes, and sometimes probiotics to manage bacterial levels and improve symptoms.